Skip to main content
Arterra Bioscience logo

Arterra Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · IT0005386369 LEI · 8156006E67B9AB95E292 XMIL Manufacturing
Open in API
Filings indexed 113 across all filing types
Latest filing 2025-07-31 Regulatory Filings
Country IT Italy
Listing XMIL ABS

About Arterra Bioscience

https://arterrabio.it/en/

Arterra Bioscience is a biotechnology company focused on the research, development, and production of innovative ingredients and natural solutions. The company develops high-value-added active ingredients derived from natural sources through sustainable biotechnologies. Its core technological platforms include in vitro bioassays, plant cell cultures, in vitro and ex vivo models of skin and intestine, and recombinant protein production. The production process utilizes techniques like freeze-drying to create stable, preservative-free raw materials. These products are applied across various industrial sectors, including cosmetics, nutraceuticals, pharmaceuticals, agriculture, food, and medical devices.

Recent filings

Filing Released Lang Actions
ARTERRA BIOSCIENCE S.P.A. HA CEDUTO L’INTERA PARTECIPAZIONE DETENUTA NEL CAPITALE SOCIALE DI LONGEVITY BIOSCIENCE S.R.L.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the sale of a subsidiary (Longevity Bioscience S.r.l.) by Arterra Bioscience S.p.A. This type of corporate activity, involving the divestment of a business unit, falls under M&A (Mergers and Acquisitions) activity. Since the document is a formal announcement of a transaction, it is classified as M&A Activity (TAR).
2025-07-31 Italian
ARTERRA BIOSCIENCE S.P.A.: FATTURATO AL 30 GIUGNO 2025 PARI A CIRCA 2,6 MILIONI DI EURO
Earnings Release Classification · 100% confidence The document is a press release dated July 18, 2025, announcing the revenue ('FATTURATO') for the period ending June 30, 2025. It provides key financial highlights (revenue figures and percentage changes) and includes commentary from the CEO. This format, focusing on preliminary or key results for a specific period (in this case, H1 2025, though the title mentions June 30th, which is the end of Q2/H1), strongly aligns with an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), as it explicitly states the figures are 'non sottoposto a revisione contabile' (not subject to audit review) and focuses only on revenue highlights, which is characteristic of an ER. H1 2025
2025-07-18 Italian
Arterra - Allegato A (Manager) - Notifica di comunicazione
Director's Dealing Classification · 100% confidence The document is a formal notification template written in Italian, titled 'MODELLO DI NOTIFICA E DI COMUNICAZIONE PREVISTO DALL'ALLEGATO AL REGOLAMENTO DI ESECUZIONE (UE) 2016/523'. It details a transaction ('Acquisto' - Purchase) involving shares of Arterra Bioscience S.p.A. by a member of the Board of Administration ('Membro del Consiglio di Amministrazione'). This structure, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing (insider trades). The specific filing type for reporting personal share transactions by company directors and executives is 'DIRS'.
2025-06-23 Italian
ARTERRA - CAMBIAMENTO SOSTANZIALE IN MATERIA DI ASSETTI PROPRIETARI
Major Shareholding Notification Classification · 98% confidence The document is titled "Comunicato Stampa ai sensi dell'art. 17 del Regolamento Emittenti Euronext Growth Milan" (Press Release pursuant to Art. 17 of the Euronext Growth Milan Issuer Regulations) and its subject is "CAMBIAMENTO SOSTANZIALE IN MATERIA DI ASSETTI PROPRIETARI" (Substantial Change in Ownership Structure). The content details a shareholder (Alberto Previtali) crossing the 15% ownership threshold, listing all significant shareholders. This type of mandatory disclosure regarding changes in major shareholdings is specifically covered by the definition for Major Shareholding Notification (MRQ). Although it is a press release, the core information is the change in ownership structure, which is a specific regulatory filing type, making MRQ more precise than the general Regulatory Filing (RNS) or Report Publication Announcement (RPA). The document length (4532 chars) is sufficient to contain the primary information, not just an announcement of an attachment.
2025-06-23 Italian
ARTERRA BIOSCIENCE S.P.A. PARTECIPA ALL’EVENTO “FINANCIAL GALÀ” ORGANIZZATO DA INTEGRAE SIM IL 19 GIUGNO 2025
Report Publication Announcement Classification · 99% confidence The document is explicitly titled "Comunicato Stampa" (Press Release) and announces the company's participation in an upcoming event ("Financial Galà") on June 19, 2025. It details who will attend and where the presentation materials will be made available. Crucially, it is a short announcement (4470 characters) informing the market about an activity, rather than being the full report itself (like an 10-K or IR). Since it is a general regulatory announcement that doesn't fit the specific categories like DIV, DIRS, or ER, it falls best under the general Regulatory Filings category (RNS), or potentially RPA if it were announcing the publication of a report, but here it announces participation in an event. Given the nature of a press release announcing corporate activity, RNS is the most appropriate general regulatory filing code.
2025-06-12 Italian
ARTERRA - FINANZIAMENTO E CONCESSIONE AGEVOLAZIONI PER IL PROGETTO “SmartLAB 2.0” DAL VALORE DI CIRCA € 3 MILIONI
Capital/Financing Update Classification · 95% confidence The document is explicitly titled "Comunicato Stampa" (Press Release) and announces that a project ("SmartLAB 2.0") has been admitted for financing and concession of aid, detailing the project scope and the amount of non-repayable contribution received (€ 2,053,672.00). This is a specific corporate announcement regarding financing and capital structure changes, not a full financial report (like 10-K or IR) or a general regulatory filing (RNS). The most appropriate category among the provided definitions is 'Capital/Financing Update' (CAP). Although it is a press release, the content is highly specific to financing, making CAP a better fit than the general RNS or RPA.
2025-05-19 Italian

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.